ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Omicron specific antibody Hot |Claudin 18.2 |Cadherin-17
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > LY75

LY75

概要

Name:Lymphocyte antigen 75
Target Synonym:LY75,CD205,Lymphocyte Antigen 75,C-Type Lectin Domain Family 13 Member B,CLEC13B,DEC-205,CD205 Antigen,Gp200-MR6,Ly-75
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
LY5-H52H3 Human Human LY75 / CD205 Protein, His Tag
LY5-H52H3-structure
LY5-H52H3-sds
LY5-M52H5 Mouse Mouse LY75 / CD205 Protein, His Tag (MALS verified)
LY5-M52H5-structure
LY5-M52H5-sds
ACRO Quality

生物活性データの一部

LY5-M52H5-BLI
Mouse LY75, His Tag (Cat. No. ) MALS images

The purity of Mouse LY75, His Tag (Cat. No. LY5-M52H5) is more than 90% and the molecular weight of this protein is around 210-255 kDa verified by SEC-MALS.

Report
  • Background
    lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.
  • Clinical and Translational Updates
      

  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6

Background

Clinical and Translational Updates

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Rasdegafusp alfa CDX-1401 Phase 2 Clinical Ludwig Institute For Cancer Research Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Melanoma; Leukemia, Myeloid, Acute; Endometrial Neoplasms; Uterine Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Astrocytoma; Colorectal Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Sarcoma; Ovarian Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Oligodendroglioma; Anemia, Refractory; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Glioblastoma; Colonic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Skin Melanoma Details
MEN-1309 MEN-1309; OBT-076; MEN1309/OBT076 Phase 1 Clinical Oxford Biotherapeutics Ltd, Menarini Solid tumours; Head and Neck Neoplasms; Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap